ASH Annual Meeting Abstracts
Dec 13, 2023
Odronextamab Trial: Striking Response Rates and Enduring Outcomes in High-Risk R/R DLBCL Subgroups
Date of Abstract presentation10th December 2023IndicationsDiffuse Large B-cell lymphoma (DLBCL)Abstract Number436Abstract typeOral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-c...
Read More...
Dec 13, 2023
Pirtobrutinib Monotherapy: A Promising Beacon of Efficacy and Safety in Relapsed/Refractory Follicular Lymphoma Patients
Date of Abstract presentation10th December 2023IndicationsFollicular LymphomaAbstract Number3026Abstract typeOral According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. Add...
Read More...
Dec 12, 2023
EPCORE NHL-1 Trial Reveals Promising Response Rates for Investigational Follicular Lymphoma Therapy: A Game-Changing Alternative in Focus
Date of Abstract presentation9th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number1655Abstract typePoster Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, which is considered incurable and can be difficult to treat in the R/R setting. EPCORE NHL-1 is a multi-center tria...
Read More...
Dec 12, 2023
Liso-cel (lisocabtagene maraleucel) Shines in Second-Line, Yielding Long-Lasting Complete Responses for Non-Transplant Eligible LBCL Patients
Date of Abstract presentation9th December 2023IndicationsLarge B-cell lymphoma (LBCL)Abstract Number105Abstract typeOral For those patients with large B-cell lymphoma (LBCL) who remain uncured following initial treatment, the conventional approach for second-line therapy has been the utilization of high-dose che...
Read More...
Dec 12, 2023
Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment
Date of Abstract presentation9th December 2023IndicationsChronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)Abstract Number330Abstract typeOral TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymp...
Read More...
Dec 11, 2023
Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Manageable Safety as a Second-Line Treatment for Relapsed Follicular Lymphoma
Date of Abstract presentation10th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number602Abstract typeOral In the TRANSCEND FL study, 130 individuals grappling with relapsed or refractory follicular lymphoma (FL) were actively involved and subjected to BREYANZI treatment within the second-line and thi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
